Australian pharma patentees now face an uphill battle to obtain interlocutory injunctions
Shutterstock/ChameleonsEye
The tide has turned against rights holders in recent years, write Gavin Adkins and Jacqueline Simpkin of Griffith Hack – though an accompanying trend of expedited trials offers some consolation
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now